Bi C - Search Results

1

Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.

Xie Z, Bi C, Cheong LL, Liu SC, Huang G, Zhou J, Yu Q, Chen CS, Chng WJ. Xie Z, et al. Among authors: bi c. PLoS One. 2011;6(6):e21583. doi: 10.1371/journal.pone.0021583. Epub 2011 Jun 24. PLoS One. 2011. PMID: 21720561 Free PMC article.

2

miRNA deregulation in multiple myeloma.

Bi CL, Chng WJ. Bi CL, et al. Chin Med J (Engl). 2011 Oct;124(19):3164-9. Chin Med J (Engl). 2011. PMID: 22040573 Review.

3

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.

Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ. Zhou J, et al. Among authors: bi c. Blood. 2011 Sep 8;118(10):2830-9. doi: 10.1182/blood-2010-07-294827. Epub 2011 Jul 6. Blood. 2011. PMID: 21734239 Free article.

4

Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival.

Reghunathan R, Bi C, Liu SC, Loong KT, Chung TH, Huang G, Chng WJ. Reghunathan R, et al. Among authors: bi c. Oncotarget. 2013 Aug;4(8):1230-40. doi: 10.18632/oncotarget.1145. Oncotarget. 2013. PMID: 23985559 Free PMC article.

5

MicroRNA: important player in the pathobiology of multiple myeloma.

Bi C, Chng WJ. Bi C, et al. Biomed Res Int. 2014;2014:521586. doi: 10.1155/2014/521586. Epub 2014 Jun 3. Biomed Res Int. 2014. PMID: 24991558 Free PMC article. Review.

6

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, Poon LF, Xie Z, Palaniyandi S, Yu H, Glaser KB, Albert DH, Davidsen SK, Chen CS. Zhou J, et al. Among authors: bi c. Blood. 2009 Apr 23;113(17):4052-62. doi: 10.1182/blood-2008-05-156422. Epub 2009 Jan 14. Blood. 2009. PMID: 19144991 Free article.

7

PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy.

Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, Mahara S, Tay KG, Zeng Q, Li J, Guo K, Tan CP, Yu H, Albert DH, Chen CS. Zhou J, et al. Among authors: bi c. PLoS One. 2011 May 12;6(5):e19798. doi: 10.1371/journal.pone.0019798. PLoS One. 2011. PMID: 21589872 Free PMC article.

8

The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia.

Zhou J, Cheong LL, Liu SC, Chong PS, Mahara S, Bi C, Ong KO, Zeng Q, Chng WJ. Zhou J, et al. Among authors: bi c. Mol Cancer. 2012 Sep 21;11:72. doi: 10.1186/1476-4598-11-72. Mol Cancer. 2012. PMID: 22995644 Free PMC article.

9

EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.

Yan J, Ng SB, Tay JL, Lin B, Koh TL, Tan J, Selvarajan V, Liu SC, Bi C, Wang S, Choo SN, Shimizu N, Huang G, Yu Q, Chng WJ. Yan J, et al. Among authors: bi c. Blood. 2013 May 30;121(22):4512-20. doi: 10.1182/blood-2012-08-450494. Epub 2013 Mar 25. Blood. 2013. PMID: 23529930 Free article.

10

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.

Bi C, Chung TH, Huang G, Zhou J, Yan J, Ahmann GJ, Fonseca R, Chng WJ. Bi C, et al. Oncotarget. 2015 Sep 22;6(28):26508-18. doi: 10.18632/oncotarget.4769. Oncotarget. 2015. PMID: 26164366 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,292 results

Search Page

Filters